Correlation between free and total vancomycin serum concentrations in patients treated for Gram-positive infections

被引:68
作者
Berthoin, Karine [1 ,2 ]
Ampe, Els [1 ,2 ,3 ]
Tulkens, Paul M. [1 ,2 ]
Carryn, Stephane [1 ,2 ,4 ]
机构
[1] Univ Catholique Louvain, Unite Pharmacol Cellulaire & Mol, B-1200 Brussels, Belgium
[2] Univ Catholique Louvain, Louvain Drug Res Inst, B-1200 Brussels, Belgium
[3] Clin Univ UCL Mt Godinne, B-5530 Yvoir, Belgium
[4] Eumed Pharmaceut, B-7170 Manage, Belgium
关键词
Protein binding; Free fraction; Vancomycin; Reversed-phase HPLC; Serum; Therapeutic drug monitoring; RESISTANT STAPHYLOCOCCUS-AUREUS; PROTEIN-BINDING; GLYCOPEPTIDE ANTIBIOTICS; BLOOD; PHARMACODYNAMICS; NEPHROTOXICITY; THERAPY; PLASMA;
D O I
10.1016/j.ijantimicag.2009.08.005
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Routine therapeutic drug monitoring (TDM) reports only total vancomycin (VAN) concentrations, although protein binding varies and it is generally accepted that only free VAN is active. The aims of this study were to examine the correlation between free and total VAN concentrations in order to estimate whether free VAN levels can be predicted based on its total concentration. A high-performance liquid chromatography (HPLC) method was set up and validated (against routine laboratory immunoassays) for measurement of free [ultrafiltration (Centrifree(R)); cut-off 30 kDa] and total [solid-phase extraction (Oasis(R) MCX cartridge)] VAN in serum. Samples (n = 65) from patients (n = 15) treated by continuous infusion were analysed. There was a wide variation in free to total VAN ratios [range 12-100%; mean 63.6+/-25.8%, with 59 values falling outside the 95% confidence interval (57.3-69.9%); median 70.2%]. The correlation between free and total VAN was poor (R-2 = 0.55). Artefacts such as pH variation of sera could be excluded. Both intrapatient and interpatient variabilities were large and no correlation could be made with patients' clinical conditions. Total VAN concentration is not predictive of free VAN concentration, suggesting that actual determination of free VAN might be recommended as an improved method of TDM. (C) 2009 Elsevier B.V. and the International Society of Chemotherapy. All rights reserved.
引用
收藏
页码:555 / 560
页数:6
相关论文
共 34 条
[21]   PERSISTENCE OF VANCOMYCIN IN BLOOD DURING RENAL FAILURE AND ITS TREATMENT BY HEMODIALYSIS [J].
LINDHOLM, DD ;
MURRAY, JS .
NEW ENGLAND JOURNAL OF MEDICINE, 1966, 274 (19) :1047-&
[22]   Vancomycin: A 50-year reassessment [J].
Moellering, RC .
CLINICAL INFECTIOUS DISEASES, 2006, 42 :S3-S4
[23]   Area under the inhibitory curve and a pneumonia scoring system for predicting outcomes of vancomycin therapy for respiratory infections by Staphylococcus aureus [J].
Moise, PA ;
Forrest, A ;
Bhavnani, SM ;
Birmingham, MC ;
Schentag, JJ .
AMERICAN JOURNAL OF HEALTH-SYSTEM PHARMACY, 2000, 57 (20) :S4-S9
[24]   Pharmacodynamics of vancomycin and other antimicrobials in patients with Staphylococcus aureus lower respiratory tract infections [J].
Moise-Broder, PA ;
Forrest, A ;
Birmingham, MC ;
Schentag, JJ .
CLINICAL PHARMACOKINETICS, 2004, 43 (13) :925-942
[25]   Tissue concentrations: do we ever learn? [J].
Mouton, Johan W. ;
Theuretzbacher, Ursula ;
Craig, William A. ;
Tulkens, Paul M. ;
Derendorf, Hartmut ;
Cars, Otto .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2008, 61 (02) :235-237
[26]   High vancomycin dosage regimens required by intensive care unit patients cotreated with drugs to improve haemodynamics following cardiac surgical procedures [J].
Pea, F ;
Porreca, L ;
Baraldo, M ;
Furlanut, M .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2000, 45 (03) :329-335
[27]  
Rybak Michael, 2009, Am J Health Syst Pharm, V66, P82, DOI [10.2146/ajhp080434, 10.1086/600877]
[28]   The pharmacokinetic and pharmacodynamic properties of vancomycin [J].
Rybak, MJ .
CLINICAL INFECTIOUS DISEASES, 2006, 42 :S35-S39
[29]   Vancomycin MIC creep in non-vancomycin-intermediate Staphylococcus aureus (VISA), vancomycin-susceptible clinical methicillin-resistant S-aureus (MRSA) blood isolates from 2001-05 [J].
Steinkraus, Gregory ;
White, Roger ;
Friedrich, Lawrence .
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2007, 60 (04) :788-794
[30]   The role of vancomycin in the treatment paradigm [J].
Stevens, DL .
CLINICAL INFECTIOUS DISEASES, 2006, 42 :S51-S57